How Much Does Evenity (Romosozumab) Cost in New Mexico in 2026?

Evenity Retail Price in New Mexico

The manufacturer list price for Evenity (romosozumab-aqqg) in New Mexico is approximately $1,825 per monthly dose in 2026. Each dose consists of two 105 mg/1.17 mL prefilled syringes administered as subcutaneous injections, totaling 210 mg per visit. The FDA-approved prescribing information specifies a fixed 12-month treatment course, making the total undiscounted cost roughly $21,900.

This price is consistent across New Mexico retail pharmacies because romosozumab is typically obtained through specialty pharmacy channels rather than standard retail dispensing. Amgen and UCB, the co-developers, set the wholesale acquisition cost (WAC) nationally. Actual out-of-pocket expense depends entirely on your insurance arrangement.

Romosozumab earned FDA approval in April 2019 based on two large phase 3 trials. The FRAME trial (N=7,180) demonstrated that romosozumab reduced new vertebral fractures by 73% compared to placebo at 12 months. The ARCH trial (N=4,093) showed romosozumab followed by alendronate cut clinical fractures by 27% compared to alendronate alone over a median 33-month follow-up period. These fracture reduction numbers justify the cost for patients at high risk, but the price remains a barrier without coverage.

New Mexico Medicaid and Evenity

New Mexico Medicaid does not cover Evenity (romosozumab) as of 2026. The New Mexico Human Services Department's preferred drug list excludes romosozumab from its formulary, placing it among several high-cost specialty biologics that require alternative coverage pathways.

This exclusion affects a significant population. According to CMS enrollment data, New Mexico has one of the highest per-capita Medicaid enrollment rates in the country. Patients relying on Medicaid who need anabolic osteoporosis therapy may be directed toward teriparatide (Forteo), which has Medicaid coverage in most states and demonstrated vertebral fracture risk reduction of 65% in its original trial (N=1,637).

For Medicaid patients whose physicians believe romosozumab is medically necessary, several options exist. Providers can submit a prior authorization exception request through the New Mexico Medicaid fee-for-service portal. The Amgen Safety Net Foundation provides free medication to qualifying uninsured or underinsured patients. Denial appeals through the state's fair hearing process represent another route, though outcomes vary.

The Endocrine Society's 2020 clinical practice guideline recommends romosozumab as first-line therapy for postmenopausal women with very high fracture risk, defined as recent osteoporotic fracture, T-score of <-3.0, or high FRAX probability. A prescriber citing this guideline may strengthen a prior authorization exception request.

Insurance Coverage Across New Mexico Plans

Most commercial insurers and Medicare Part B cover Evenity in New Mexico, though all require prior authorization and documentation of high fracture risk. Coverage criteria typically demand a confirmed osteoporosis diagnosis via DXA scan with a T-score of -2.5 or below, history of fragility fracture, or failure of a prior antiresorptive agent.

Medicare Part B covers romosozumab under the buy-and-bill model because it is an injectable administered by a healthcare provider. The Part B coinsurance rate is 20% after the annual deductible, meaning a patient without supplemental coverage would pay approximately $365 per monthly injection. Medicare Advantage plans may impose different step-therapy requirements. The AACE 2020 osteoporosis guideline classifies romosozumab-eligible patients as "very high risk," a designation that can support medical necessity documentation for Medicare.

Blue Cross Blue Shield of New Mexico and Presbyterian Health Plan, the two largest commercial carriers in the state, both include Evenity on their specialty pharmacy formularies with tier 4 or specialty tier placement. Prior authorization through these plans generally requires documentation of: a qualifying DXA T-score, at least one prior bisphosphonate trial or documented intolerance, and no history of myocardial infarction or stroke within the preceding 12 months.

That cardiovascular screening criterion stems from the ARCH trial safety signal. The FDA label carries a boxed warning noting a higher rate of major adverse cardiovascular events (MACE) in the romosozumab group compared to the alendronate group (2.5% vs. 1.9% at the end of the open-label period). Insurers universally enforce cardiovascular risk screening before authorization.

How the Amgen / UCB Savings Card Works in New Mexico

The Amgen Evenity copay savings card is the single most effective cost-reduction tool for commercially insured patients in New Mexico. The program covers up to $1,825 per injection for eligible patients, effectively reducing the copay to $0 for most enrollees. It covers all 12 doses in the treatment course.

Eligibility requirements are straightforward. Patients must have commercial insurance that covers Evenity, must not be enrolled in any federal or state healthcare program (Medicare, Medicaid, TRICARE, VA), and must be a resident of the United States. New Mexico residents with qualifying commercial insurance can enroll through the manufacturer's website or by calling the support line directly.

The savings card works at the point of dispensing. The specialty pharmacy submits the claim to the patient's primary insurance first, then applies the copay card as a secondary payer. For commercially insured patients whose plan covers Evenity but assigns a high copay or coinsurance (common with specialty tier drugs), this effectively eliminates the out-of-pocket burden.

Patients without commercial insurance or those on federal programs should contact the Amgen Safety Net Foundation, which provides Evenity at no cost to patients meeting income thresholds (generally <300% of the federal poverty level). The National Osteoporosis Foundation (now Bone Health & Osteoporosis Foundation) also maintains a resource directory for patient assistance programs across all osteoporosis medications.

Compounded Romosozumab in New Mexico

Compounded romosozumab is legally available through 503A-licensed compounding pharmacies in New Mexico. Under federal law (FDCA Section 503A), a licensed pharmacist may compound a drug based on a valid patient-specific prescription when certain conditions are met, including that the compounded product is not essentially a copy of a commercially available drug.

That last condition is the critical legal nuance. The FDA has enforced against compounders who produce copies of commercially available biologics, and romosozumab is a monoclonal antibody with complex post-translational modifications that require mammalian cell culture systems for production. A true 503A compounded version of romosozumab, an anti-sclerostin monoclonal antibody, would face substantial manufacturing and regulatory challenges.

Patients considering a compounded product should verify that the pharmacy holds a current New Mexico Board of Pharmacy compounding license, ask whether the product undergoes potency and sterility testing, and confirm that their prescriber is comfortable monitoring treatment response with serial DXA scans and bone turnover markers like P1NP (procollagen type 1 N-terminal propeptide), which spikes dramatically during romosozumab therapy and serves as a reliable marker of drug activity.

Telehealth Prescribing for Evenity in New Mexico

New Mexico permits telehealth prescribing of Evenity. The New Mexico Medical Board recognizes telehealth as an acceptable modality for establishing and maintaining the physician-patient relationship, which means an initial osteoporosis consultation can legally occur via video visit.

The practical workflow involves a telehealth consultation with an endocrinologist or rheumatologist, followed by an in-person visit at a local clinic or infusion center for the actual injection. Some patients in rural New Mexico counties (where specialist access is limited) may find telehealth particularly useful for obtaining the prescription and prior authorization, then receiving injections at a local provider's office.

DXA scans and laboratory work (calcium, vitamin D, renal function, P1NP) still require in-person visits at imaging and lab facilities. The ISCD 2019 official positions specify standardized DXA acquisition and analysis protocols that cannot be replicated remotely.

Comparing Evenity Costs to Other Osteoporosis Drugs in NM

Romosozumab is the most expensive osteoporosis treatment per treatment course, but a direct cost comparison requires accounting for efficacy differences and total treatment duration.

Alendronate (generic Fosamax): approximately $10 to $30 per month for oral tablets. The FIT trial (N=2,027) showed a 47% reduction in hip fracture risk over 3 years. Indefinite treatment duration is common, with bisphosphonate drug holidays recommended after 5 years for moderate-risk patients.

Denosumab (Prolia): approximately $1,600 to $1,800 per injection every 6 months. Annual cost is roughly $3,200 to $3,600. The FREEDOM trial (N=7,868) demonstrated a 68% reduction in vertebral fractures over 3 years. Treatment is ongoing, and discontinuation causes rapid bone loss rebound with increased vertebral fracture risk.

Teriparatide (Forteo): approximately $3,400 per month for the daily injectable. A 24-month course totals roughly $81,600 at list price. The Neer et al. trial (N=1,637) showed a 65% vertebral fracture risk reduction.

Romosozumab: at $1,825/month for 12 months, the total course cost of $21,900 is substantially less than a full teriparatide course. The FRAME extension data showed that patients who received romosozumab for 12 months followed by denosumab continued to gain BMD, with total hip BMD increasing 3.2% during the romosozumab phase.

Reducing Your Evenity Costs in New Mexico: A Step-by-Step Approach

The most reliable path to affordable romosozumab treatment in New Mexico follows this sequence. First, confirm your fracture risk qualifies under FRAX assessment or meets the very-high-risk criteria in the Endocrine Society guideline. Second, verify your insurance formulary status and submit prior authorization with supporting DXA results, fracture history, and cardiovascular clearance documentation. Third, enroll in the Amgen copay savings card if commercially insured, or apply to the Amgen Safety Net Foundation if uninsured or on a non-covered government plan.

For patients whose insurance denies coverage, a formal appeal citing the ARCH and FRAME trial data and the AACE/Endocrine Society guideline recommendations has a reasonable success rate. Include the specific fracture risk reduction data: 73% vertebral fracture reduction at 12 months in FRAME, and 27% clinical fracture reduction versus alendronate alone in ARCH.

New Mexico patients should also ask their prescriber about the appropriate antiresorptive transition agent after completing the 12-month romosozumab course, as the bone-forming gains from sclerostin inhibition are lost without follow-on therapy. The Cosman et al. 2017 analysis confirmed that sequential therapy with denosumab preserved and extended BMD gains achieved during the romosozumab phase, with lumbar spine BMD reaching 17.6% above baseline at 24 months in the romosozumab-to-denosumab sequence.